Compare Hims and Hers Health Inc (HIMS) vs VF Corp (VFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs VF Corp — how do they compare? Hims and Hers Health Inc trades at $28.32 (market cap $6.89B), while VF Corp trades at $14.52 (market cap $5.65B). The key difference: Hims and Hers Health Inc is the larger of the two by market cap, and VF Corp pays a 2.5% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and VF Corp for 64 Days on average.
| HIMS | VFC | |
|---|---|---|
Market Cap | $6.89B | $5.65B |
Volume | 5,446,628 | 6,542,273 |
Sector | Health | Consumer Cyclical |
52-Week High | $62.76 | $21.55 |
52-Week Low | $14.52 | $12.62 |
Typical Hold Time | 21 Days | 64 Days |
Enterprise Value | $7.60B | $9.94B |
Dividend Yield | — | 2.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hims & Hers Health trades at $29.54, up 0.24% on the day, with a bullish technical signal from moving averages but mixed earnings performance. Revenue grew to $2.35 billion in 2025, yet the company posted a net loss of $142 million in 2026, reflecting profitability challenges. High valuation ratios like a P/E of 57.14 and negative ROE of -32.03% indicate premium pricing despite weak earnings. Recent news highlights multiple securities class action lawsuits filed in October 2026, creating legal overhangs.
The stock faces headwinds from profitability struggles and legal risks, but analyst consensus remains a Buy with a $32.17 price target, suggesting modest upside. Investment appeal hinges on resolving operational inefficiencies and legal issues to align valuation with fundamentals, while current sentiment is cautious due to recent earnings misses and regulatory scrutiny.
VFC trades at $14.53, up 0.55% with a bullish technical signal from moving averages. The company reported mixed quarterly results, beating in Q4 2025 but missing in subsequent quarters. Revenue declined from $11.8B in 2022 to $9.5B in 2025, with net losses in recent years. Analyst consensus shows 41% buy ratings with an $18.33 price target, while the stock faces execution risks from Vans brand weakness despite stronger Outdoor segment performance.
The outlook remains cautious with valuation appearing reasonable (P/E 20.84, P/S 0.6) but dependent on successful turnaround execution. Key risks include persistent Vans weakness, high debt levels, and competitive pressures. Upside potential exists if management can stabilize revenue and improve profitability, but investors face significant execution uncertainty in the apparel sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →
